UBS Faces Client Backlash Over Options Strategy
A complex investment strategy pitched as low-risk by stockbrokers at UBS has triggered a backlash from clients of its securities unit.
Amazon Deal Opens Door to Bigger Footprint in India
Amazon has signed an agreement that would give it the option to take a significant stake in one of India's largest retailers.
Google Disables YouTube Channels It Linked to Hong Kong Influence Operation
Google pulled 210 YouTube channels from its platform, saying that they appeared to be part of a coordinated disinformation campaign in response to pro-democracy protests in Hong Kong.
CMA Orders RBS and Santander to Fix PPI Breaches
The U.K.'s Competition and Markets Authority ordered Royal Bank of Scotland and Santander U.K. to fix payment protection insurance breaches after they failed to properly inform thousands of customers that they had the policy.
GW Pharmaceuticals in Talks With U.K. Regulator Over Epilepsy Drugs
A U.K. health watchdog said that it is in talks with GW Pharmaceuticals over recommending the company's cannabis-derived medicine for use by the country's National Health Service to treat epilepsy.
India's Oyo Buys Las Vegas Hooters Hotel
Oyo Hotels & Homes and its partner Highgate pay $135 million for the Hooters Casino Hotel in Las Vegas as part of a global expansion.
FAA Seeks Pilots' Input to Establish New 737 MAX Procedures
The U.S. Federal Aviation Administration is asking pilots from airlines that fly the Boeing Co. 737 MAX to participate in simulator testing to help validate new procedures for the plane that was grounded in March following two crashes.
Walmart to Reopen El Paso Store Months After Shooting
Walmart plans to reopen the El Paso store where a gunman killed 22 people, but it will first entirely renovate the interior and add an on-site memorial.
Some Coca-Cola Stocks Fizz More Than Others
Coca-Cola is supposed to have the same flavor everywhere, but that's not the case for Coca-Cola stocks. Some of the soda giant's bottling partners offer fizzier growth than others.
FDA Focuses on Novartis Delay in Reporting Drug-Test Data Manipulation
Regulators examining test data manipulation for a gene-therapy drug made by Novartis are zeroing in on the company's two-month delay in launching a formal inquiry.